Home › Delirium › NCT06969287

Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery

Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery (MD FluNCS)

Who can join

Ages 60 and older · All sexes

Inclusion Criteria:

* English-speaking
* elective non-cardiac or non-intracranial surgery requiring at least a 2-day hospital length of stay

Exclusion Criteria:

* Received investigational drug within the last 7 weeks
* lack of capacity to provide informed consent
* prior known intolerance or allergy to SSRIs or fluvoxamine
* planned postoperative ventilation
* drug or alcohol dependence
* preoperative use of non-NSAID medications with drug-drug interactions of Class X (Avoid Combination) or D (Consider Therapy Modification)
* risk of serotonin syndrome (St John's Wort, SSRIs, or TCA)

About the study

The investigation will establish biological plausibility and infrastructure required for a multisite clinical trial evaluating the re-purposing of fluvoxamine to mitigate postoperative delirium risk in geriatric patients undergoing non-cardiac non-intracranial surgery.

What is being tested

• Fluvoxamine (drug)
• Placebo (drug)

Sponsor: Washington University School of Medicine · Participants: 46 · Started: Apr 6, 2026

Contact the study team

• Sarah Knarr · Phone: 3143622415

Official record on ClinicalTrials.gov — NCT06969287

Locations in the U.S.

Conditions

• Delirium

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.